Literature DB >> 19389308

Bovine colostral antibody against verotoxin 2 derived from Escherichia coli O157:H7: resistance to proteases and effects in beagle dogs.

Takashi Kuribayashi1, Tetsuro Seita, Mariko Matsumoto, Katsunori Furuhata, Kazutoshi Tagata, Shizuo Yamamoto.   

Abstract

A bovine colostral antibody against verotoxin (VT) 2 of Escherichia coli O157:H7 was administered orally to beagle dogs. The antibody remained in the dogs' small intestine for at least 2 h, whereas little serum antibody remained 1.5 h after administration. Furthermore, the antibody activity of secretory IgA did not change until 2 h after administration; however, the activity of IgG and IgM antibodies decreased by approximately 60% and 40% at 2 h after administration, respectively. Seven beagle dogs inoculated with Escherichia coli O157:H7 producing VT2 were administered bovine colostral antibody or bovine colostral whey without antibody. With administration of bovine colostral whey without antibody, the amount of VT2 in feces decreased gradually after administration and increased again at 5 d after inoculation, whereas bovine colostral antibody significantly reduced the amount of VT2 in feces on the day after administration. In addition, 9 beagle dogs were given bovine colostral antibody, bovine plasma antibody, or saline. The amount of VT2 in feces again decreased significantly more rapidly after administration of bovine colostral antibody than after administration of bovine plasma antibody or saline.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19389308      PMCID: PMC2703148     

Source DB:  PubMed          Journal:  Comp Med        ISSN: 1532-0820            Impact factor:   0.982


  28 in total

1.  The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections.

Authors:  C S Wong; S Jelacic; R L Habeeb; S L Watkins; P I Tarr
Journal:  N Engl J Med       Date:  2000-06-29       Impact factor: 91.245

Review 2.  Structure and function of immunoglobulin A.

Authors:  T B Tomasi; H M Grey
Journal:  Prog Allergy       Date:  1972

Review 3.  A review of secretory immune mechanisms.

Authors:  A G Plaut
Journal:  Am J Clin Nutr       Date:  1972-12       Impact factor: 7.045

4.  Secretory IgA, a major immunoglobulin in most bovine external secretions.

Authors:  J P Mach; J J Pahud
Journal:  J Immunol       Date:  1971-02       Impact factor: 5.422

5.  Proteolytic degradation of exocrine and serum immunoglobulins.

Authors:  W R Brown; R W Newcomb; K Ishizaka
Journal:  J Clin Invest       Date:  1970-07       Impact factor: 14.808

6.  Studies on the structural and conformational basis for the relative resistance of serum and secretory immunoglobulin A to proteolysis.

Authors:  B J Underdown; K J Dorrington
Journal:  J Immunol       Date:  1974-03       Impact factor: 5.422

7.  Fluorescent localization of immunoglobulins in the tissues of the cow.

Authors:  A M Yurchak; J E Butler; T B Tomasi
Journal:  J Dairy Sci       Date:  1971-09       Impact factor: 4.034

8.  Comparison of the effect of elastase on human secretory IgA and serum IgA.

Authors:  A Tax; L Korngold
Journal:  J Immunol       Date:  1971-10       Impact factor: 5.422

Review 9.  The role of Shiga-toxin-producing Escherichia coli in hemorrhagic colitis and hemolytic uremic syndrome.

Authors:  Thomas G Cleary
Journal:  Semin Pediatr Infect Dis       Date:  2004-10

10.  Thiolated chitosans: development and in vitro evaluation of an oral tobramycin sulphate delivery system.

Authors:  Juliane Hombach; Herbert Hoyer; Andreas Bernkop-Schnürch
Journal:  Eur J Pharm Sci       Date:  2007-09-08       Impact factor: 4.384

View more
  3 in total

1.  Evaluation of biological safety in vitro and immunogenicity in vivo of recombinant Escherichia coli Shiga toxoids as candidate vaccines in cattle.

Authors:  Katharina Kerner; Philip S Bridger; Gabriele Köpf; Julia Fröhlich; Stefanie Barth; Hermann Willems; Rolf Bauerfeind; Georg Baljer; Christian Menge
Journal:  Vet Res       Date:  2015-04-10       Impact factor: 3.683

Review 2.  Approaches to treatment of emerging Shiga toxin-producing Escherichia coli infections highlighting the O104:H4 serotype.

Authors:  Elias A Rahal; Sukayna M Fadlallah; Farah J Nassar; Natalie Kazzi; Ghassan M Matar
Journal:  Front Cell Infect Microbiol       Date:  2015-03-18       Impact factor: 5.293

Review 3.  The Role of Escherichia coli Shiga Toxins in STEC Colonization of Cattle.

Authors:  Christian Menge
Journal:  Toxins (Basel)       Date:  2020-09-21       Impact factor: 4.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.